Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.72 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.72 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.72 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.72 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.69 |
| ▸ | P2RY2 | P41231 | 13/20 | 0.68 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.68 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4948478 | 0.90 | SLC28A1 (0.69) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL6369206 | 0.90 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL2168191 | 0.89 | SLC28A1 (0.70) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL6053985 | 0.88 | SLC28A1 (0.74) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL425155 | 0.88 | SLC28A1 (0.74) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL5846586 | 0.88 | SLC28A1 (0.74) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL17627530 | 0.88 | SLC28A1 (0.66) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL42134 | 0.87 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL7618891 | 0.87 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL566229 | 0.87 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146286-A1 | SMALL RNA-BASED PROGNOSTIC SIGNATURES AND THERAPEUTIC COMPOSITIONS FOR IDIOPATHIC PULMONARY FIBROSIS | GATEHOUSE BIO INC. (US) | 2026-05-28 | — | — | US | disclosed |
| WO-2024015640-A2 | SMALL RNA-BASED PROGNOSTIC SIGNATURES AND THERAPEUTIC COMPOSITIONS FOR CORONARY MICROVASCULAR DYSFUNCTION | GATEHOUSE BIO, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-2900679-B1 | 5-FLUOROURIDINE DERIVATIVES | BRAUN MELSUNGEN AG (DE) | 2020-07-01 | — | — | EP | disclosed |
| US-9914914-B2 | Polymerase capable of producing non-DNA nucleotide polymers | MEDICAL RESEARCH COUNCIL (GB) | 2018-03-13 | — | — | US | disclosed |
| US-9902752-B2 | 5-fluorouracil derivatives | B. BRAUN MELSUNGEN AG (DE) | 2018-02-27 | — | — | US | disclosed |
| US-9486521-B2 | Therapeutic applications targeting SARM1 | UNIVERSITY OF MASSACHUSETTS (US) | 2016-11-08 | — | — | US | disclosed |
| US-20150291649-A1 | 5-Fluorouracil Derivatives | B. BRAUN MELSUNGEN AG (DE) | 2015-10-15 | — | — | US | disclosed |
| US-20150275192-A1 | POLYMERASE CAPABLE OF PRODUCING NON-DNA NUCLEOTIDE POLYMERS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2015-10-01 | — | — | US | disclosed |
| EP-2900679-A1 | 5-FLUORUORACIL DERIVATIVES | B. Braun Melsungen AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-20140079712-A1 | Therapeutic Applications Targeting SARM1 | UNIVERSITY OF MIAMI (US) | 2014-03-20 | — | — | US | disclosed |
| US-20070204357-A1 | Process for producing normal parenchymal cells, tissues or organs by bioincubator | YUKI ATSUSHI | 2007-08-30 | — | — | US | disclosed |
| US-20040072350-A1 | Process for producing normal parenchymal cells tissue or organ by bioincubator | DIAMOND, PAUL | 2004-04-15 | — | — | US | disclosed |
| EP-1135022-A4 | PLASTIN PROMOTER DIRECTED GENE THERAPY | UNIV YALE (US) | 2003-07-09 | — | — | EP | disclosed |
| EP-1323821-A1 | PROCESS FOR PRODUCING NORMAL PARENCHYMAL CELLS, TISSUE OR ORGAN BY BIOINCUBATOR | Yuki, Atsushi (JP) | 2003-07-02 | — | — | EP | disclosed |
| EP-1135022-A1 | PLASTIN PROMOTER DIRECTED GENE THERAPY | YALE UNIVERSITY (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-1060182-A2 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | Metabasis Therapeutics, Inc. (US) | 2000-12-20 | — | — | EP | disclosed |
| WO-2000033655-A1 | PLASTIN PROMOTER DIRECTED GENE THERAPY | YALE UNIVERSITY (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-1999045016-A9 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS INC (US) | 2000-03-02 | — | — | WO | disclosed |
| WO-1999045016-A2 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS, INC. (US) | 1999-09-10 | — | — | WO | disclosed |
| US-5849905-A | Biologically active phosphotriester-type nucleosides and methods for preparing same | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1998-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291649-A1 | 5-Fluorouracil Derivatives | DPYD, FAU, DHFR | SLC28A1 1007/4885SLC28A2 1074/4885SLC29A1 473/4885 |
| US-20260146286-A1 | SMALL RNA-BASED PROGNOSTIC SIGNATURES AND THERAPEUTIC COMPOSITIONS FOR IDIOPATHIC PULMONARY FIBROSIS | RBM26, RBM28, RBM25 | SLC28A1 370/4885SLC28A2 488/4885SLC29A1 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.